DMD # 74336
until aliquoted for radioanalysis and centrifuged to obtain plasma. For Group 4 animals, one animal/sex/time point was euthanized via exsanguination (cardiac puncture) under isoflurane anesthesia predose and at 1, 6, 12, 24, and 48 hours postdose and as much blood as possible was collected into tubes containing K 2 EDTA anticoagulant. Samples were maintained on wet ice until centrifuged to obtain plasma.
Radioactivity Measurement. Blood and plasma were treated with a solubilizing agent and incubated for at least 1 h at approximately 60°C. Di-sodium EDTA (0.1 M) and hydrogen peroxide (30%) were added and samples were allowed to sit at least overnight to remove foaming and color. Ultima Gold XR scintillation cocktail was added and the samples were shaken and analyzed by liquid scintillation counting (LSC). Urine, bile, cage wash, and cage rinse were mixed with scintillation cocktail and duplicate weighed aliquots were analyzed by Reconstitution volumes were approximately 0.5 and 1.5 ml for plasma and feces extracts, respectively. Pooled urine and bile samples were vortex mixed and centrifuged to remove insoluble solids then analyzed.
LC-MS and Radioprofile Analysis. Liquid chromatography (LC) was performed using a 1200
Series system (Agilent Technologies, Santa Clara, CA) with a Luna C18(2) column (250×4.6 mm, 5 µm particle size, Phenomenex, Torrance, CA) that was heated constantly to 30 o C. The LC flow rate was 1.0 ml/min with mobile phases of 10 mM ammonium acetate, pH 5.0 (mobile phase A) and ACN (mobile phase B). A 57-min gradient elution was used with the following program: initial holding at 5% B for 5 min, then increasing to 30% B over 39 min, then increased to 95% B over 1 min and holding for 5 min to flush the column; and this was followed by reequilibration at 5% B for 7 min before the next injection. The column effluent was split with approximately 25% diverted to the mass spectrometer and 75% to the radiometric detector or, for samples with less total radioactivity, a fraction collector for offline radiodetection. Online radioactivity measurements were made using a 610 TR radiodetector (Perkin Elmer) with a 0.5 mL flow cell and Ultima Flo M scintillation cocktail at a flow rate of 3 mL/min. Offline radioactivity measurements were made by collection of 10 second intervals per well into 96-well LumaPlate-96 microplates (Perkin Elmer) and analysis by TopCount NXT scintillation and luminescence counter (Perkin Elmer).
A separate liquid chromatography method was developed to retain and confirm the identity of 9 DMD # 74336 phases of 0.005% diethylamine in water (mobile phase A) and 0.005% diethylamine in methanol (mobile phase B). The LC flow rate was 1.0 mL/min. Analytes were eluted from the column with the following gradient: initial holding at 0% B for 5 min, then increased to 50% B over 15 min, then increased to 95% B over the following 5 min and held for 5 min to flush the column. The column was re-equilibrated for 5 min at 5% B before the next injection.
A LTQ Orbitrap XL high resolution mass spectrometer (Thermo Scientific, San Jose, CA) was used to obtain full scan and product ion spectra for metabolite identification. Column eluent was introduced with an electrospray ionization source with voltage set at 5 kV and heated capillary at 275°C. The capillary and tube lens voltages were set at 40 and 95 V, respectively. The full scan event cycle was used as a survey scan upon which MS/MS scans were completed following collision induced dissociation and higher energy collision dissociation.
In Vitro Incubations to Identify Decyanation Products. Metabolic reactions contained microsomal protein (0.5 mg/ml) in potassium phosphate, pH 7.4 (100 mM) supplemented with magnesium chloride (3 mM) and NADPH (1 mM). Reactions were initiated by adding GDC-0425 (5 µM). For metabolite-searching experiments, an equimolar mix of natural and deuterated (d 9 -piperidine ) GDC-0425 was incubated so that the isotope ratio would confirm that an analyte originated from the test compound. At the end of the incubation (60 min), the reactions were quenched with three volumes of cold ACN, and proteins were precipitated. The supernatants were concentrated under vacuum for analysis.
Similar incubations were conducted with liver microsomes and either d 0 -GDC-0425 or d 9 -GDC-0425 as substrate under an atmosphere of 18 O 2 . Similar experimental setups have been previously
reported by other investigators to confirm the contribution of P450s (Zhang et al., 2002) . The
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Results
Mass Balance, Excretion Profiles, and Pharmacokinetics of Radioactivity. No differences were observed between male and female rats in the rates or extent of recoveries for radioactivity; therefore, data were grouped and are described with the average of all animals. After a single oral administration of [ Table 1 and the metabolic pathways for GDC-0425 observed in rats are summarized in Figure 3 .
To confirm the identity of the early-eluting radioactivity, a second chromatographic method was employed that retained highly-polar analytes and provided MS confirmatory information.
Analysis of authentic standards for thiocyanate and cyanide demonstrated that this method was successful at chromatographically retaining and resolving these analytes (elution at 6 and 11 min, respectively) and enabled identifying them based on their MS molecular ions. The early-eluting radioactivity in plasma was confirmed to be thiocyanate with its retention time matching the This article has not been copyedited and formatted. The final version may differ from this version. Table 2 . GDC-0425 reached its maximal plasma concentrations of 6.5 µM at 1 h post-dose with a terminal half-life of 3.6 h. Its exposure accounted for 36.1% of plasma radioactivity (AUC 0-48 h ). The radioprofiles of plasma at later time points indicated the major circulating species was thiocyanate (Figure 2 ).
Thiocyanate accounted for 37.0% of plasma radioactivity (AUC 0-48 h ), was observed at its maximal concentration of 0.73 µM at 12 h post-dose and then declined at the same rate as total radioactivity. The other abundant circulating metabolites were present at lower levels and included M10 (N-deethyl) and M16 (ketone metabolite), which accounted for 3.2 and 9.0% of plasma radioactivity (AUC 0-48h ), respectively.
The profiles of GDC-0425 and its metabolites in urine, feces, and bile are summarized in Table   2 . GDC-0425 in bile was negligible, but in urine accounted for 11% of the dose, indicating the contribution of renal clearance. Unchanged GDC-0425 in feces accounted for only 5.3% of the dose, which indicated that the oral dose had been well-absorbed and that the majority of clearance was by metabolism. The major metabolites in urine were M10 (N-deethylation) and M5 (O-dealkylation), which accounted for 9.7% and 3.6% of the dose, respectively. In bile, the M6 (hydroxylation and glucuronidation) and M9 (hydroxylation) were observed and accounted for 10.6 and 5.3% of the dose, respectively. In feces, the major metabolites were M7 (Ndealkylation and hydroxylation), M9 (hydroxylation), and M10 (N-deethylation), which accounted for 5.0%, 22.9%, and 11.6.3% of the dose, respectively. The remaining radioactivity This article has not been copyedited and formatted. The final version may differ from this version. -0.51 ppm). The base peak in the MS/MS spectrum was observed at m/z 112, which corresponded to unchanged N-ethylpiperidine, and other identifying product ions were observed at m/z 202 and 268, which were generated via cleavages of the piperidine ring ( Figure 5 ). These ions were consistent with replacement of the nitrile of GDC-0425 with a hydroxyl. , and 20 mg/kg of GDC-0425, respectively. As observed with rats, thiocyanate exposures did not differ between the first dose and repeated dose for any of the dose groups.
Discussion
To support the clinical development of GDC-0425, a radiolabeled rat mass balance and metabolite identification study was conducted. The ease of addition of [ 14 C]nitrile group in the final synthetic step was one reason for the placement of the radiolabel. The risk of losing the radiolabel was assessed in vitro, which indicated that it was stable. Following a single oral administration at 10 mg/kg (200 µCi/kg), the radioactive dose was rapidly and well absorbed.
Clearance was mainly through oxidative metabolism (65% of the administered dose) and renal
This article has not been copyedited and formatted. The final version may differ from this version. The long apparent half-life for plasma radioactivity (63 h) was not anticipated based on in vitro or in vivo PK (non-radiolabeled) studies. Radioprofiling of the plasma samples confirmed this to be attributed to an unexpected polar metabolite (M1) in plasma that retained the radiotracer. Subsequent experiments using a Hypercarb column allowed this analyte to be chromatographically retained and showed it to be a single chromatographic peak that was identified as thiocyanate. This analysis also provided selective quantification of the drug-derived thiocyanate, which reached a maximal plasma concentration of approximately 0.7 µM followed by a slow decline that explained the long-lived circulating radioactivity (Figure 4 ).
Radioprofiling of excreta samples showed that thiocyanate was eliminated in urine, bile, and feces (≤0.3% of the dose per elimination route). It was evident based on retention of the radiolabel that thiocyanate had originated from GDC-0425, which indicated that GDC-0425 had undergone a decyanation reaction and the released cyanide had been efficiently converted to thiocyanate. The latter was well-supported by the known high activities for rhodonase. The decyanation reaction accounted for less than 1% of the GDC-0425 dose; however, it was a pronounced observation due to the low volume of distribution and slow clearance of thiocyanate and the placement of 14 C at the nitrile group.
Metabolic cyanide release is a relatively uncommon reaction (Fleming et al., 2010) , 1981; Koch and Palicharla, 1990) . Though there was precedence for cyanide being metabolically released from a drug, these proposed mechanisms did not satisfactorily describe how it had occurred from GDC-0425. In this case, the nitrile group was attached to an aromatic ring system, which would presumably be less susceptible for carbon-carbon cleavage.
A decyanation product, M18, was observed in the rat and human liver microsomes incubation samples. Based on mass spectrometric data, the nitrile of GDC-0425 was replaced with hydroxyl group. The formation of this metabolite was NADPH-dependent and more extensive in liver microsomes from dexamethasone pre-treated rats compared to those from vehicle pre-treated rats, which were suggestive that P450s were involved. Based on M18 as the putative primary product of the P450-mediated decyanation reaction, we propose the mechanism shown in Figure 7 . We describe nucleophilic addition of the P450 peroxo-anion intermediate species to carbon-2 of pyridine (step 1). This reaction center could be rationalized to be determined by the electron-withdrawing nitrogen and nitrile moiety.
In a concerted rearrangement of this tetrahedral transition state, the O-O bond is cleaved and cyanide anion is released (step 2). This product can then tautomerize to its pyridine-2-ol form, M18 (step 3). We have considered formation of an electrophilic intermediate, such as epoxide, at pyridine, then oxygen addition which displaces the nitrile; however, in vitro trapping studies using the thiol-containing reagents glutathione and cysteine provided no evidence of this intermediate. Further, though we describe the oxidation reaction as a two-electron addition to the aromatic ring, it is possible that this reaction could occur via a single electron abstraction forming a delocalized radical cation that binds an activated oxygen species of P450. Several sources have described these reactions and the observations supporting these possible mechanisms (Vaz, 2003; Ortiz de Montellano and De Voss, 2005; Testa and Kramer, 2008) .
Though decyanation had occurred as a minor metabolic pathway in rats, it was judged prudent to assess its extent in repeated dose studies of GDC-0425 in rats and monkeys. In these studies, total plasma (endogenous plus GDC-0425-derived) thiocyanate concentrations were monitored and demonstrated there were no differences between animals receiving vehicle or any tested dose of GDC-0425. Further, there were no observed effects on respiration rates or oxygen saturation levels and no CNS findings that would be indicative of cyanide or thiocyanate toxicity. These data confirmed the findings from the in vitro and radiolabeled rat studies and further supported that GDC-0425-derived thiocyanate was negligible. The corresponding in vitro human data were indicative that decyanation reaction would be minor in humans. To make a conservative assessment of clinical risk, a scenario of an extreme case of decyanation was considered. If 2% of administered GDC-0425 underwent decyanation (magnitudes greater than predicted based on in vitro and preclinical evidence), the starting clinical dose of 60 mg QD could result in an addition of approximately 1 μM thiocyanate to systemic levels. This would contribute negligibly to endogenous thiocyanate, which exists at significantly higher and highly variable concentrations of 34 µM in serum and up to 100 µM in smokers (Foss and Lund-Larsen, 1986 ).
In the phase 1 first-in-human clinical trial, GDC-0425 was orally administered daily at 60 mg or 80 mg in combination with a standard dose of gemcitabine to cancer patients (Infante et al., 2016) . Measurements of total plasma thiocyanate were included in the patient monitoring, which demonstrated that thiocyanate levels were unchanged following GDC-0425 administration and remained below 150 µM for all subjects (Shin et al., 2015) . These results confirmed the negligible contribution to systemic thiocyanate by decyanation of GDC-0425 in humans and demonstrated the conservative nature of the clinical risk assessment that assumed 2% of the dose undergoing conversion to thiocyanate. These findings were part of the clinical safety profile of GDC-0425 established in the phase I study.
In conclusion, P450 enzymes catalyzed the release of cyanide from GDC-0425, which was subsequently converted to systemic thiocyanate in vivo. A radiolabeled study of GDC-0425 demonstrated that this metabolic pathway was a minor route of clearance. Thiocyanate levels were determined in multiple-dose toxicological studies of GDC-0425 in rats and monkeys and indicated that there were no increases in systemic thiocyanate concentrations arising from GDC-0425 administration. These pre-clinical studies supported that thiocyanate formation was This article has not been copyedited and formatted. The final version may differ from this version. 
